Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B
![Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B](https://pubs.acs.org/cms/10.1021/acs.jpcb.2c03193/asset/images/medium/jp2c03193_0015.gif)
Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B
![Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B](https://pubs.acs.org/cms/10.1021/acs.jpcb.2c03193/asset/images/medium/jp2c03193_0002.gif)
Antimicrobial Peptide Mechanism Studied by Scattering-Guided Molecular Dynamics Simulation | The Journal of Physical Chemistry B
![Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study - Gary J. Connett, Katharine C. Pike, Julian P. Legg, Katrina Cathie, Ann Dewar, Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study - Gary J. Connett, Katharine C. Pike, Julian P. Legg, Katrina Cathie, Ann Dewar,](https://journals.sagepub.com/cms/10.1177/1753465815601571/asset/images/large/10.1177_1753465815601571-fig2.jpeg)
Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study - Gary J. Connett, Katharine C. Pike, Julian P. Legg, Katrina Cathie, Ann Dewar,
![Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects](https://www.mdpi.com/pathogens/pathogens-10-01638/article_deploy/html/images/pathogens-10-01638-g005-550.jpg)
Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
![PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies](https://www.researchgate.net/publication/303795031/figure/fig5/AS:372577022300173@1465840692978/MICs-mg-mL-of-the-bacteria-strains-tested-by-time-kill-studies_Q320.jpg)
PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
![PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale](https://www.researchgate.net/profile/Rik-Oldenkamp/publication/331265767/figure/fig2/AS:1132451426500609@1647008868365/Concentrations-of-carbamazepine-a-green-and-ciprofloxacin-b-purple-over-the_Q320.jpg)
PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale
![PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale](https://www.researchgate.net/profile/Rik-Oldenkamp/publication/331265767/figure/fig4/AS:1132451426500614@1647008868739/Box-whisker-plots-comparing-measured-concentrations-yellow-and-modelled-concentrations_Q320.jpg)
PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale
![PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies](https://www.researchgate.net/publication/303795031/figure/fig2/AS:372572916076565@1465839713929/MIC50-MIC90-and-modal-MICs-for-each-bacteria-and-antibiotics_Q320.jpg)
PDF) Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
![PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale](https://www.researchgate.net/profile/Rik-Oldenkamp/publication/331265767/figure/fig5/AS:1132451426500623@1647008868942/Aquatic-risks-AR-per-ecoregion-expressed-as-the-PEC-PNEC-ratios-for-the-total-water_Q320.jpg)
PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale
![Types-of-Pneumonias - Brief overview of the entitled topic - PNEUMONIAS NAME SPECIFICS CLINICAL - StuDocu Types-of-Pneumonias - Brief overview of the entitled topic - PNEUMONIAS NAME SPECIFICS CLINICAL - StuDocu](https://d20ohkaloyme4g.cloudfront.net/img/document_thumbnails/d51386199d4acbbf9bc85917d83869e1/thumb_1200_1698.png)
Types-of-Pneumonias - Brief overview of the entitled topic - PNEUMONIAS NAME SPECIFICS CLINICAL - StuDocu
![Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects](https://www.mdpi.com/pathogens/pathogens-10-01638/article_deploy/html/images/pathogens-10-01638-g006-550.jpg)
Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
![Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects](https://www.mdpi.com/pathogens/pathogens-10-01638/article_deploy/html/images/pathogens-10-01638-g001.png)
Pathogens | Free Full-Text | β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
![PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale PDF) Aquatic risks from human pharmaceuticals—modelling temporal trends of carbamazepine and ciprofloxacin at the global scale](https://www.researchgate.net/profile/Rik-Oldenkamp/publication/331265767/figure/fig1/AS:1132451422306333@1647008867816/Temporal-trends-in-global-consumption-of-carbamazepine-a-green-and-ciprofloxacin_Q320.jpg)